Share on StockTwits

St. Jude Medical, Inc. (NYSE:STJ) issued an update on its FY14 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $3.95-4.00 for the period, compared to the Thomson Reuters consensus estimate of $3.97, ARN reports. The company issued revenue guidance of $5.61-5.76 billion, compared to the consensus revenue estimate of $5.69 billion.St. Jude Medical also updated its Q2 guidance to $0.99-1.01 EPS.

Shares of St. Jude Medical, Inc. (NYSE:STJ) opened at 63.22 on Wednesday. St. Jude Medical, Inc. has a one year low of $40.31 and a one year high of $68.79. The stock’s 50-day moving average is $65.78 and its 200-day moving average is $61.56. The company has a market cap of $17.942 billion and a P/E ratio of 25.39.

St. Jude Medical (NYSE:STJ) last issued its quarterly earnings data on Wednesday, April 16th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.01. The company had revenue of $1.36 million for the quarter, compared to the consensus estimate of $1.36 million. During the same quarter in the previous year, the company posted $0.92 earnings per share. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, analysts predict that St. Jude Medical, Inc. will post $3.98 earnings per share for the current fiscal year.

A number of research firms have recently commented on STJ. Analysts at EVA Dimensions upgraded shares of St. Jude Medical from an overweight rating to a buy rating in a research note on Wednesday, March 5th. On a related note, analysts at Raymond James downgraded shares of St. Jude Medical from an outperform rating to a market perform rating in a research note on Tuesday, February 11th. Finally, analysts at Deutsche Bank reiterated a buy rating on shares of St. Jude Medical in a research note on Monday, February 10th. They now have a $74.00 price target on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $59.32.

St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.